Tecentriq (atezolizumab) combined with chemotherapy failed to meet its primary endpoint of progression-free survival — the length of time during and after therapy in which the patient’s disease does not get worse — for the initial (first-line) treatment of PD-L1-positive individuals with metastatic triple-negative breast cancer (TNBC). These are the findings of the multicenter Phase 3 IMpassion131 study (NCT03125902), which compared Tecentriq plus the chemotherapy paclitaxel to paclitaxel alone in 651 people with previously untreated, inoperable,…
You must be logged in to read/download the full post.
The post Tecentriq-Chemotherapy Combo Falls Short in TNBC Phase 3 IMpassion131 Trial appeared first on BioNewsFeeds.